Shares of Medtronic (NYSE: MDT) are off to a fantastic start in 2025, already rising by 13% year to date. The medical devices ...

Hybrid closed-loop systems outperformed other types of subcutaneous insulin treatment for diabetes, but some systems were more efficient than others, according to results published in ...

Medtronic's MiniMed 670G - the closest thing yet to an artificial pancreas - has been launched in the US. The so-called 'hybrid closed-loop' system comprises a blood glucose sensor ...

Medtronic hired a new chief financial officer away from French carmaker Renault. Thierry Pieton, chief financial officer of ...

In diabetes care, the MiniMed 780G insulin pump system uses AI algorithms to predict and adjust insulin delivery based on real-time blood sugar monitoring. These types of features highlight just ...

Growth prospects remain bright. As type 1 and type 2 diabetes continue inflicting people, Medtronic's solutions such as MiniMed (insulin pump), InPen (real-time continuous glucose monitoring and ...

A.L.P. has been a consultant for Medtronic MiniMed and has received a grant from the Medtronic/MiniMed Foundation. She has served as a consultant and/or speaker for multiple nondevice-related ...

Diabetes mellitus is a metabolic disease that causes high blood sugar. Your body either doesn’t make enough insulin or can’t effectively use the insulin it makes. The hormone insulin moves ...

The Diabetes business unit at Medtronic (NYSE:MDT) could have some exciting offering in the pipeline, company officials say.

Since 2012, $6.2 million has been invested through the Freeport-McMoRan Foundation Community Investment Fund in Grant County. The funds have been awarded to programs and projects that help foster ...